바이오인

Understanding the research and development (R&D) pipeline for neglected diseases as well as the spectrum of organizations participating in developing these new drugs and vaccines is essential to evaluate the eciency and eectiveness of current R&D models and to inform the design of new programs and initiatives to ll gaps in the neglected disease R&D pipeline. However, this type of analysis has been hindered in part because neglected disease pipelines have not been systematically tracked. Millions of lives could be saved through faster and more e-cient R&D. It is critical to target our resources and R&D eorts to provide the greatest benet to the world’s poor.